Cargando…

American Society of Clinical Oncology’s Global Oncology Leadership Task Force: Findings and Actions

In response to rising cancer incidence and mortality rates in low- and middle-income countries and the increasingly global profile of ASCO’s membership, the ASCO Board of Directors appointed the Global Oncology Leadership Task Force (Task Force) to provide recommendations on ASCO’s engagement in glo...

Descripción completa

Detalles Bibliográficos
Autores principales: Hortobagyi, Gabriel N., Pyle, Doug, Cazap, Eduardo L., El Saghir, Nagi S., Shulman, Lawrence N., Lyman, Gary H., Schnipper, Lowell E., Adebamowo, Clement Adebayo, Gandara, David R., Vose, Julie, Wong, Sandra L., Yu, Peter
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society of Clinical Oncology 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6180769/
https://www.ncbi.nlm.nih.gov/pubmed/30241187
http://dx.doi.org/10.1200/JGO.17.00060
_version_ 1783362278067798016
author Hortobagyi, Gabriel N.
Pyle, Doug
Cazap, Eduardo L.
El Saghir, Nagi S.
Shulman, Lawrence N.
Lyman, Gary H.
Schnipper, Lowell E.
Adebamowo, Clement Adebayo
Gandara, David R.
Vose, Julie
Wong, Sandra L.
Yu, Peter
author_facet Hortobagyi, Gabriel N.
Pyle, Doug
Cazap, Eduardo L.
El Saghir, Nagi S.
Shulman, Lawrence N.
Lyman, Gary H.
Schnipper, Lowell E.
Adebamowo, Clement Adebayo
Gandara, David R.
Vose, Julie
Wong, Sandra L.
Yu, Peter
author_sort Hortobagyi, Gabriel N.
collection PubMed
description In response to rising cancer incidence and mortality rates in low- and middle-income countries and the increasingly global profile of ASCO’s membership, the ASCO Board of Directors appointed the Global Oncology Leadership Task Force (Task Force) to provide recommendations on ASCO’s engagement in global oncology. To accomplish its work, the Task Force convened meetings of global oncology experts, conducted focus group discussions with member groups, did site visits to South America and India, and met regularly to analyze the findings and develop recommendations. Task Force findings included global concerns, such as access to care, and specific concerns of middle- and low-resource settings. The need to strengthen health systems and the importance of alliances with a range of international cancer stakeholders were emphasized. Task Force recommendations to the ASCO Board of Directors were based on a three-part global oncology strategy of professional development, improvement of access to quality care, and acceleration of global oncology research. Specific areas of focus within each of these strategic pillars are provided along with an update on areas of ASCO activity as these recommendations are implemented.
format Online
Article
Text
id pubmed-6180769
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher American Society of Clinical Oncology
record_format MEDLINE/PubMed
spelling pubmed-61807692018-11-13 American Society of Clinical Oncology’s Global Oncology Leadership Task Force: Findings and Actions Hortobagyi, Gabriel N. Pyle, Doug Cazap, Eduardo L. El Saghir, Nagi S. Shulman, Lawrence N. Lyman, Gary H. Schnipper, Lowell E. Adebamowo, Clement Adebayo Gandara, David R. Vose, Julie Wong, Sandra L. Yu, Peter J Glob Oncol Special Article In response to rising cancer incidence and mortality rates in low- and middle-income countries and the increasingly global profile of ASCO’s membership, the ASCO Board of Directors appointed the Global Oncology Leadership Task Force (Task Force) to provide recommendations on ASCO’s engagement in global oncology. To accomplish its work, the Task Force convened meetings of global oncology experts, conducted focus group discussions with member groups, did site visits to South America and India, and met regularly to analyze the findings and develop recommendations. Task Force findings included global concerns, such as access to care, and specific concerns of middle- and low-resource settings. The need to strengthen health systems and the importance of alliances with a range of international cancer stakeholders were emphasized. Task Force recommendations to the ASCO Board of Directors were based on a three-part global oncology strategy of professional development, improvement of access to quality care, and acceleration of global oncology research. Specific areas of focus within each of these strategic pillars are provided along with an update on areas of ASCO activity as these recommendations are implemented. American Society of Clinical Oncology 2017-08-11 /pmc/articles/PMC6180769/ /pubmed/30241187 http://dx.doi.org/10.1200/JGO.17.00060 Text en © 2017 by American Society of Clinical Oncology http://creativecommons.org/licenses/by/4.0/ Licensed under the Creative Commons Attribution 4.0 License: http://creativecommons.org/licenses/by/4.0/
spellingShingle Special Article
Hortobagyi, Gabriel N.
Pyle, Doug
Cazap, Eduardo L.
El Saghir, Nagi S.
Shulman, Lawrence N.
Lyman, Gary H.
Schnipper, Lowell E.
Adebamowo, Clement Adebayo
Gandara, David R.
Vose, Julie
Wong, Sandra L.
Yu, Peter
American Society of Clinical Oncology’s Global Oncology Leadership Task Force: Findings and Actions
title American Society of Clinical Oncology’s Global Oncology Leadership Task Force: Findings and Actions
title_full American Society of Clinical Oncology’s Global Oncology Leadership Task Force: Findings and Actions
title_fullStr American Society of Clinical Oncology’s Global Oncology Leadership Task Force: Findings and Actions
title_full_unstemmed American Society of Clinical Oncology’s Global Oncology Leadership Task Force: Findings and Actions
title_short American Society of Clinical Oncology’s Global Oncology Leadership Task Force: Findings and Actions
title_sort american society of clinical oncology’s global oncology leadership task force: findings and actions
topic Special Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6180769/
https://www.ncbi.nlm.nih.gov/pubmed/30241187
http://dx.doi.org/10.1200/JGO.17.00060
work_keys_str_mv AT hortobagyigabrieln americansocietyofclinicaloncologysglobaloncologyleadershiptaskforcefindingsandactions
AT pyledoug americansocietyofclinicaloncologysglobaloncologyleadershiptaskforcefindingsandactions
AT cazapeduardol americansocietyofclinicaloncologysglobaloncologyleadershiptaskforcefindingsandactions
AT elsaghirnagis americansocietyofclinicaloncologysglobaloncologyleadershiptaskforcefindingsandactions
AT shulmanlawrencen americansocietyofclinicaloncologysglobaloncologyleadershiptaskforcefindingsandactions
AT lymangaryh americansocietyofclinicaloncologysglobaloncologyleadershiptaskforcefindingsandactions
AT schnipperlowelle americansocietyofclinicaloncologysglobaloncologyleadershiptaskforcefindingsandactions
AT adebamowoclementadebayo americansocietyofclinicaloncologysglobaloncologyleadershiptaskforcefindingsandactions
AT gandaradavidr americansocietyofclinicaloncologysglobaloncologyleadershiptaskforcefindingsandactions
AT vosejulie americansocietyofclinicaloncologysglobaloncologyleadershiptaskforcefindingsandactions
AT wongsandral americansocietyofclinicaloncologysglobaloncologyleadershiptaskforcefindingsandactions
AT yupeter americansocietyofclinicaloncologysglobaloncologyleadershiptaskforcefindingsandactions